The QualityStocks Daily Wednesday, November 4th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (AFFU) +87.92%

Tip.us (IONKF) +82.69%

MarketClub Analysis (APVO) +51.20%

The QualityStocks Daily Stock List

Candelaria Mining Corp. (CDELF)

Gold Telegraph, Metals News, Junior Mining Network, FX Empire, Findata, Gold Stock Data, ValueTheMarkets, Cambridge House, StocksCafe, Proactive Investors, Canadian Mining Report, The Prospector News, Business Insider, Seeking Alpha, Mexico Mining Center, Market Screener, ADVFN.com, CEO.ca, Investing.com, Stockwatch, Barchart, Financial Post, Morningstar, OTC Markets, InvestorX, GlobeNewswire, Stockhouse, and MarketWatch reported beforehand on Candelaria Mining Corp. (CDELF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Candelaria Mining Corp. is a gold development and exploration company with a portfolio of highly prospective projects in Mexico. The Company is advancing its flagship project, Caballo Blanco, through technical studies with the goal of bringing the project to production. A team of highly successful individuals with comprehensive expertise in exploration, corporate finance, and mine development in Mexico leads the Company. Founded in 2012, Candelaria Mining is based in Vancouver, British Columbia and lists on the OTC Markets.

Candelaria’s 100 percent owned Caballo Blanco Project hosts an Indicated Resource of 521,000 ounces of gold and 2,170,000 ounces of silver (31,220,000 tonnes grading 0.52 g/t gold and 2.16 g/t silver). It hosts an Inferred Resource of 95,000 ounces of gold and 590,000 ounces of silver (8,630,000 tonnes grading 0.34 g/t gold and 2.14 g/t silver).

There is potential to increase these estimated resources via continued drilling and exploration. Additionally, the Company holds the Pinos Gold Project, which hosts a Measured Resource of 4,444 ounces of gold and 228,892 ounces of silver (85,847 tonnes grading 1.6 g/t gold and 82.9 g/t silver), an Indicated Resource of 20,586 ounces of gold and 267,745 ounces of silver (175,697 tonnes grading 3.6 g/t gold and 47.4 g/t silver) and an Inferred Resource of 60,657 ounces of gold and 811,082 ounces of silver (529,267 tonnes grading 3.6 g/t gold and 47.4 g/t silver).

Candelaria Mining owns about 3,800 hectares of Pinos mining concessions consisting of roughly 17km worth of veins containing Gold and Silver. The veins have been mined historically to a depth of only 180 meters, due to reaching the water table. Nevertheless, mineralization has been shown to continue at depth.

In October, Candelaria Mining announced that Mr. Mike Struthers agreed to be appointed as Chief Executive Officer (CEO) as part of a transaction to acquire the interests of Empire Metals Ltd. (AIM:EEE) in the Bolnisi gold and copper project in the Republic of Georgia. In combination with his upcoming appointment as CEO, Mr. Struthers will join Candelaria Mining's Board of Directors. Furthermore, Candelaria announced that Dr. Neil O’Brien will join the Candelaria Board as a Director.

The appointments are subject to the closing of the Transaction planned for December 7, 2020. Mr. Struthers is presently CEO with Empire Metals. He is an experienced professional and Chartered Engineer with 40 years of global mining experience. Dr. O’Brien is a consulting economic geologist and former mining executive.

Candelaria Mining Corp. (CDELF), closed Wednesday's trading session at $0.4606, up 1.7226%, on 1,200 volume with 1 trade. The average volume for the last 3 months is 1,226 and the stock's 52-week low/high is $0.03085/$0.460599988.

Home Bistro, Inc. (HBIS)

SmallCapVoice, Stockhouse, Zacks, Seeking Alpha, Morningstar, Investing.com, Market Screener, OTC Markets, MacroTrends, Stockwatch, Stockopedia, Simply Wall St, GlobeNewswire, Nasdaq, Fintel, GuruFocus, InvestorsHub, MarketBeat, Global Banking and Finance, Stockrow, docoh, FX Empire, Dividend Investor, and MarketWatch reported earlier on Home Bistro, Inc. (HBIS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Home Bistro, Inc. is a provider of high quality, direct-to-consumer, ready-made gourmet meals. The Company provides these meals at www.homebistro.com. It also provides restaurant quality meats and seafood by way of its Prime Chop www.primechop.co and Colorado Prime brands. Home Bistro has its head office in N Babylon, New York. The Company lists on the OTC Markets.

Home Bistro is a premier gourmet online meal delivery service that has been delivering meals since 2014. Home Bistro’s wider growth strategy is to respond to increasing interest in its products and to broaden its penetration of the markets it now serves in the U.S.

Pertaining to its Premium Meats, its Prime Chop offers affordable All-American Premium Meats. These include Raw and Cooked offerings. Chop also offers Samplers, such as the Steak Lover's Sampler Assortment. In addition, it offers Soups and Desserts.

Recently, SmallCapVoice.com announced the availability of a recent interview with world-renowned chef, author, and restaurateur, Ms. Cat Cora, who was joined by Zalmi Duchman, Chief Executive Officer of Home Bistro. The interview outlined the development of Home Bistro’s work with Ms. Cora, the development of the Company to date, the pandemic driven huge growth in the direct-to-consumer, ready-made meal market, as well as the objectives for the rest of this year and beyond.

Cora and Duchman explained the origin and story behind their union in establishing this new line of gourmet meals, which joins the pioneering talents of Ms. Cora with Home Bistro’s mastery of meal delivery preparation and logistics.

Zalmi Duchman said, “To continue penetrating and expanding our reach in the U.S. is our prime goal in 2021. The most exciting and rewarding thing for us will be to see how meals are improving everyday life in our new normal. We want families to eat delicious and healthy, ready-made meals without all the prep time and stress that comes with cooking. That is basically our vision. The Company is ideally positioned for scale and growth. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”

Home Bistro, Inc. (HBIS), closed Wednesday's trading session at $1.20, off by 7.6923%, on 203 volume with 3 trades. The stock's 52-week low/high is $0.850000023/$3.00.

alpha-En Corporation (ALPE)

Zacks, Stocksbeat, Invest Tribune, Otc.watch, Market Screener, PR Newswire, 4-Traders, Last10k, InvestorsHub, OTC Markets, OilandGas360, Wallet Investor, Morningstar, TradingView, Simply Wall St, and InvestorsHub reported previously on alpha-En Corporation (ALPE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corporation is an innovative clean technology company based in Yonkers, New York. It concentrates on enabling next generation battery technologies through developing and bringing to market pure, state of the art materials produced in an environmentally sustainable manner. The Company has developed a patent pending process for the production of lithium metal and associated products produced at room temperature. The Company’s first-rate Scientific Team includes a Nobel Prize winning Chemist. alpha-En’s shares trade on the OTC Markets Group’s OTCQB.

alpha-En is enabling next generation energy storage. The Company’s lithium metal is purer than what is currently available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

The Company produces its lithium utilizing a room temperature process (process conducted at 20°-30°C) that does not require or release noxious chemicals. Its process allows for the flexible deposition and intercalation of lithium into custom substrates that streamlines the manufacturing of batteries of all sizes.

alpha-En’s novel process is mercury and chlorine free. It eliminates the use and release of toxic chemicals and expensive containment costs. Its electrodeposition method produces thin films of highly pure lithium on a host of substrates. Strategic partners of the Company include Argonne National Laboratory and Princeton University.

alpha-En previously announced that it received a $1 million technology development grant from the New York State Energy Research and Development Authority (NYSERDA). The funding will help to pay for the substantial amount of research and development (R&D) that is required to bring disruptive battery technology from the laboratory to final commercialization.

Recently, alpha-En announced that it determined that it meets the requirements to be a Qualified Opportunity Business (QOZB) under the Federal Tax Cuts and Jobs Act of 2017 (TCJA). As a QOZB, alpha-En could potentially offer favorable tax treatment to investors in future placements of its securities, as specified in the TCJA. alpha-En's headquarters and laboratory facilities in Yonkers, New York, is located in an Opportunity Zone as certified by the US Treasury under the TCJA.

alpha-En Corporation (ALPE), closed Wednesday's trading session at $0.42, up 68.00%, on 30,621 volume with 17 trades. The average volume for the last 3 months is 4,869 and the stock's 52-week low/high is $0.209999993/$1.16999995.

InMed Pharmaceuticals, Inc. (IMLFF)

Awesome Penny Stocks, The Seed Investor, BioSpace, Stockhouse, Stock of the Week, Morningstar, Seeking Alpha, OTC Markets, PR Newswire, CEO.ca, WeedStreet420, Macroaxis, MarketWatch, Nasdaq, Newswire.ca, YCharts, Barchart, SmartKarma, Penny Picks, Wallet Investor, TMX.com, Make Penny Stocks Great Again, InvestorsHub, Wall Street Alerts, Proactive Investors, Daily Marijuana Observer, GuruFocus, Market Screener, Dividend.com, and MarketBeat reported beforehand on InMed Pharmaceuticals, Inc. (IMLFF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

InMed Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need. The Company is also engaged in the clinical development of cannabinol (CBN). InMed was previously known as Cannabis Technologies, Inc. It changed its name to InMed Pharmaceuticals, Inc. in October of 2014. Incorporated in 1981, InMed Pharmaceuticals has its corporate headquarters in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQX.

InMed Pharmaceuticals is developing a pipeline of cannabinoid-based medications, initially centered on the therapeutic benefits of CBN in diseases with high unmet medical need. The Company’s commitment is to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. It employs a highly scientific approach to designing and developing medicines that will help unlock the complete potential of cannabinoid pharmaceuticals.

InMed Pharmaceuticals is developing a strong, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the host of cannabinoids (100-plus) found from natural sources. The design of the Company’s products are to be bio-identical to the naturally-occurring cannabinoids and the process foreseen to provide cost and time savings, and superior ease, control, and quality of manufacturing versus alternative methods.

InMed has its INM-755. INM-755 is a CBN cream intended as a topical therapy to treat Epidermolysis Bullosa (EB) and potentially other dermatological diseases. EB is the collective name of a group of genetic disorders characterized by fragile skin and mucous membranes, which are easily damaged, leading to extensive blistering and wounding.

This past September, InMed Pharmaceuticals announced that all subjects participating in the Company’s second Phase 1 clinical trial with INM-755 have completed treatment. The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase 1 study. The design of it is to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers.

The 755-102-HV trial is being conducted at the Centre for Human Drug Research in Leiden, the Netherlands. Eight adult subjects were treated with two strengths of INM-755 cream over a 14-day treatment period. In Med Pharmaceuticals anticipates reporting results from both Phase 1 trials in the second half of calendar 2020 and, assuming a positive safety profile for INM-755, submitting regulatory filings for the first efficacy trial in EB patients in early 2021.

InMed Pharmaceuticals, Inc. (IMLFF), closed Wednesday's trading session at $4.671, off by 11.7997%, on 49,899 volume with 260 trades. The average volume for the last 3 months is 8,383 and the stock's 52-week low/high is $3.03999996/$10.6260004.

KORE Mining Ltd. (KOREF)

Stock Day Media, InvestorX, Streetwise Reports, Crux Investor, The Prospector News, Resource World, Metals News, Junior Mining Network, FX Empire, Seeking Alpha, Market Screener, Proactive Investors, Newsfilecorp, Nasdaq, Dividend.com, GuruFocus, Business Insider, Morningstar, OTC Markets, Stockwatch, Mining Stock Education, IRW Press, Wallet Investor, NS Energy, Dividend Investor, PR Newswire, CEO.ca, InvestorsHub, Mining.com, and Barchart reported earlier on KORE Mining Ltd. (KOREF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

KORE Mining Ltd. engages in the exploration and development of mineral resource properties. The Company is 100 percent owner of a portfolio of advanced gold exploration and development assets in the State of California and the Province of British Columbia. KORE Mining earlier announced a positive Preliminary Economic Assessment (PEA) on its Imperial Project. The Company is exploring to increase its gold resource base. OTCQX-listed, KORE Mining is headquartered in Vancouver, British Columbia.

The Company is supported by strategic investors Mr. Eric Sprott and Macquarie Bank who, together with the management and Board own about 64 percent of the basic shares outstanding. KORE has four 100 percent owned gold projects: two in California (Imperial and Long Valley) and two in British Columbia (FG Gold and Gold Creek).

KORE has two main value-added channels. One is Exploration - deploying a strategic investment from Mr. Sprott, it is exploring at three of its four projects to increase its already large gold resource base. The second value-added channel is Developing Imperial – deploying a strategic investment from Macquarie Bank, KORE Mining released a strong PEA on its flagship Imperial Oxide Gold Project ($343 Million NPV 5% and 44% IRR). The Company’s 100 percent owned Imperial Project is in California within nine miles of the Mesquite mine (owned by Equinox Gold).

Furthermore, the 100 percent owned Long Valley project hosts a large near-surface epithermal gold-silver deposit 2.5 km long that is exposed at surface. In addition, the 100 percent owned FG Gold project is positioned in the Cariboo area of British Columbia. It is easily accessible by gravel road. Moreover, KORE Mining’s 100 percent owned Gold Creek project is in the Cariboo region of British Columbia, 8 km northwest of the Spanish Mountain project. In 2018, gold mineralization was drilled.

KORE Mining has increased its land holding in the Cariboo Gold District of British Columbia by 330 percent. The Company is now the dominant land holder of the southern half of the District with Osisko Gold Royalties Ltd.'s (TSX:OR) Barkerville/Cariboo Gold Project controlling the north. Highlights include a consolidated 1,000 square kilometer land position in the southern Cariboo Gold District. KORE's claims host 110 km of the Eureka thrust structural trend. The Trend is highly prospective for orogenic gold deposits. It is 100 percent KORE Mining owned.

Last week, KORE Mining announced filing of the NI 43-101 Technical Report entitled "Preliminary Economic Assessment – Technical Report for the Long Valley Gold Project, California, USA" for the earlier announced positive Preliminary Economic Assessment (PEA) for its 100 percent owned Long Valley Gold Deposit in California. The results of the PEA were reported in its press release dated September 15, 2020. In finalizing the report, minor revisions to a number of estimates increased the after-tax NPV5% by US$ 10 million to US$ 273 million from the results of the previous press release. The effective date of the PEA is September 21, 2020. The technical report was filed on October 27, 2020.

KORE Mining Ltd. (KOREF), closed Wednesday's trading session at $0.95, off by 9.5238%, on 36,269 volume with 55 trades. The average volume for the last 3 months is 87,796 and the stock's 52-week low/high is $0.090800002/$1.48000001.

NewAge, Inc. (NBEV)

MarketWatch, Stocktwits, Investors Observer, Stock of the Week, Stocklight, MacroTrends, Barchart, Stockhouse, Stockopedia, docoh, Invest Chronicle, Wallet Investor, Investing.com, Morningstar, YCharts, Finviz, Insider Tracking, MarketBeat, ShareInvestor.com, TMXmoney, Stocknews, GlobeNewswire, GuruFocus, ETF.com, Nasdaq, InvestorsHub, Invest Million, Seeking Alpha, Market Screener, Infront Analytics, Market Chameleon, and Weedstreet420 reported earlier on NewAge, Inc. (NBEV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NewAge, Inc. is a healthy and organic products company. It has a network of independent business owners across 75 countries worldwide. Its dedication is to inspiring and educating consumers to “Live Healthy.” The Company is an omni-channel distribution business with access to traditional retail, e-commerce, direct-to-consumer, and medical channels. Founded in 2010, NewAge is based in Denver, Colorado. The Company lists on the Nasdaq Capital Market (NasdaqCM).

In late July 2020, NewAge announced that it changed its name to NewAge, Inc. from New Age Beverages Corporation to reflect the strategic priorities of the business and to be representative of the substantial opportunities it sees in the broader consumer products goods space. This change follows the prior announcement to combine with ARIIX and four additional e-commerce and direct selling companies. This will create a global organization with estimated pro forma revenues in excess of $500 million across more than 75 countries.

In June of 2019, NewAge merged with Brands Within Reach, LLC (BWR) to expand its retail presence and product portfolio. In February of this year NewAge launched Noni+CBD shots in Japan, as one of the first major companies to gain approval from the Japanese Ministry of Health. In March of this year, NewAge launched TeMana Shape, the first product specifically formulated to support intermittent fasting, into a number of key markets worldwide.

NewAge markets a portfolio of better-for-you products. These include the brands Tahitian Noni, the aforementioned TeMana, Nestea, Volvic, Illy Coffee, Evian, Búcha Live Kombucha, ‘Nhanced, as well as others. NewAge markets a portfolio of differentiated healthy functional brands in three category platforms. These include Health & Wellness, Healthy Appearance, as well as Nutritional Performance. The Company operates the websites newage.com, noninewage.com, and several other individual brand websites.

At the beginning of October, NewAge announced that it amended the merger agreement for the acquisition of ARIIX, and that it expects to close the transaction no later than November 30, 2020. Details of the amended and restated agreement and plan of merger are included in its Current Report on Form 8-K dated October 1, 2020.

Furthermore, in October, New Age announced that it has expanded operations to Brazil, one of the six largest direct selling markets globally.

Mr. Brent Willis, Chief Executive Officer of NewAge, said, “The building of the Brazil market is yet another important step in our strategy to bring our products and brands through our omni-channel strategy to emerging markets around the globe. Everything we have done with our Brazil expansion has been very local and very Brazilian, which is a must to be successful. Providing access to the market opportunity there for all our reps from all our partner companies is a great benefit for them, and a great growth opportunity for us.”

NewAge will release financial results for its Q3 ended September 30, 2020, before the stock market opens on Monday, November 9, 2020. It will hold a conference call and webcast for investors at 8:00 a.m. Eastern Time that same day.

NewAge, Inc. (NBEV), closed Wednesday's trading session at $2.71, up 0.743494%, on 1,729,937 volume with 6,906 trades. The average volume for the last 3 months is 1,985,950 and the stock's 52-week low/high is $0.981000006/$3.22000002.

Sona Nanotech, Inc. (SNANF)

Hot Stocks Review, Investing News, InvestorsHub, Proactive Investors, Dividend Investor, StockInvest.us, InvestorX, FX Empire, Investing.com, Simply Wall St, Stockhouse, GuruFocus, Newsfilecorp, Investor Welcome, Stockwatch, Baystreet.ca, Barchart, Dividend.com, CEO.ca, and Seeking Alpha reported previously on Sona Nanotech, Inc. (SNANF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sona Nanotech, Inc. is a nanotechnology life sciences company listed on the OTCQB. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by the Company is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms, which it says will improve performance over existing tests in the market. Sona Nanotech produces high-quality gold nanorod products for diagnostic tests and medical treatment applications. The Company is headquartered in Halifax, Nova Scotia.

Sona Nanotech states that its innovative gold nanorods will power the next generation of lateral flow diagnostics. Its gold nanorod products feature a highly functionalized and strong manufacturing process. They are multicolored and CTAB (cetyltrimethylammonium) free. Furthermore, they have a long shelf life; functionalized surface properties; typical widths are between 10 and 15 nm; and lengths are from 25-60 nm.

The Company’s products include Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, Gemini 1050NM, and Omni. Gemini is for Point of Care diagnostics (lateral flow tests, Elisa, electro-chemical biosensors). Omni is for medical applications (drug delivery, photothermal therapy, and cell imaging).

Regarding its Conjugation Service, Sona Nanotech can combine a client’s biologicals with its nanorods to offer a completely optimized conjugate for their assays, decreasing their development time. Concerning Lateral Flow Test Development, Sona provides a tailored, modular contract development service from proof of concept through to full development and transfer to production.

Pertaining to Lateral Flow Test Production, the Company is partnered with world-class, third-party manufacturers. This is to manufacture pilot and validation batches through to large-scale bulk volumes to serve a client’s market.

At the end of August 2020, Sona Nanotech announced it engaged Bonham/Wills & Associates, a top sports consulting firm, to assist in securing test development sponsorship partners for its next rapid-response test research and development (R&D) project, taking advantage of Sona's proprietary gold nanorod technology. Bonham/Wills is to identify partners to participate in the development of a prototype and eventual field validation for a test for mild-traumatic brain injury (mTBI), typically referred to as concussion. Partners will be asked to support continuing test development, optimization, validation, and also field studies with a view to obtaining regulatory approval worldwide.

Yesterday, Sona Nanotech announced the appointment of Mr. J. Mark Lievonen, C.M., to its Board of Directors. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. At present, Mr. Lievonen is the Co-Chair of the Government of Canada's COVID-19 Vaccine Task Force, a Director of OncoQuest Pharmaceuticals Inc., Biome Grow, Inc., and the Gairdner Foundation.

Sona Nanotech, Inc. (SNANF), closed Wednesday's trading session at $2.7965, off by 2.9802%, on 13,213 volume with 40 trades. The average volume for the last 3 months is 71,272 and the stock's 52-week low/high is $0.063885003/$11.9799995.

TRACON Pharmaceuticals, Inc. (TCON)

GlobeNewswire, Stockhouse, Zacks, BioPharmCatalyst, Stocktwits, ETF.com, InvestorsHub, iwatchmarkets, Stocknews, The Stock Market Watch, Investors Observer, Stockwatch, Seeking Alpha, YCharts, Investing.com, Nasdaq, Morningstar, Proactive Investors, Market Screener, TradingView, Wallet Investor, BioPharmaJournal, Simply Wall St, MacroTrends, Barchart, TipRanks, ChartMill, and TMXmoney reported earlier on TRACON Pharmaceuticals, Inc. (TCON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. Its goal is to be a leader in the development of targeted therapies for patients with cancer and other diseases of high unmet need. The Company formerly went by the name Lexington Pharmaceuticals, Inc. It changed its corporate name to TRACON Pharmaceuticals, Inc. in March of 2005. Established in 2004, TRACON Pharmaceuticals is based in San Diego, California. The Company lists on the Nasdaq Capital Market (NasdaqCM).

TRACON’s clinical-stage pipeline includes Envafolimab. This is a subcutaneous PD-L1 single-domain antibody undergoing development for the treatment of sarcoma with the objective of starting a registrational trial in the United States in the second half of 2020.

Furthermore, TRACON Pharmaceuticals’ pipeline includes TRC253. This is a small molecule drug candidate undergoing development for the treatment of prostate cancer. In addition, the Company’s pipeline includes TRC102. This is a small molecule drug candidate undergoing development for the treatment of lung cancer. TRACON’s pipeline also includes TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors.

TRACON earlier announced the clearance of the pivotal ENVASARC protocol after filing the protocol with the U.S. Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application on July 15, 2020. This application cross referenced the open envafolimab IND maintained by TRACON’s corporate partners 3D Medicines and Alphamab Oncology. TRACON expects to initiate enrollment in the ENVASARC trial at 25 sites in the United States in this Q4 of 2020.

Currently, Envafolimab is dosing in a Phase 2 registration trial as a single agent in MSI-H/dMMR advanced solid tumor patients and a Phase 3 registration trial in combination with gemcitabine and oxaliplatin in advanced biliary tract cancer patients in China.

In late October, TRACON Pharmaceuticals announced that the FDA granted TRC102 orphan drug designation for the treatment of patients with malignant glioma, including glioblastoma (GBM). TRC102 is a small molecule inhibitor of the DNA base excision repair pathway. TRC102 is being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute via a Cooperative Research and Development Agreement (CRADA).

Recently, TRACON Pharmaceuticals announced that it will report its Q3 2020 financial and operating results after the close of U.S. financial markets on Tuesday, November 10, 2020. Moreover, Company Management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

TRACON Pharmaceuticals, Inc. (TCON), closed Wednesday's trading session at $4.99, up 2.6749%, on 239,428 volume with 1,096 trades. The average volume for the last 3 months is 1,582,773 and the stock's 52-week low/high is $0.949999988/$6.36999988.

Falcon Minerals Corporation (FLMN)

Stockhouse, Dividend.com, GuruFocus, Morningstar, TipRanks, ADVFN, ETF.com, Investors Observer, Seeking Alpha, Mining Stock Education, Street Insider, Barchart, Investing.com, Insider Monkey, Dividend Channel, YCharts, docoh, ETF Channel, Simply Wall St, Fintel, last10k, Dividend Investor, Nasdaq, Finviz, Market Screener, MarketWatch, MarketBeat, and Businesswire reported earlier on Falcon Minerals Corporation (FLMN), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Falcon Minerals Corporation is an oil & gas minerals company listed on the NasdaqGS. It owns mineral rights positions in the “core-of-the-core” of the Eagle Ford Shale in south Texas. The Company is a C-Corporation created to own and acquire high growth oil-weighted minerals rights. Its Revenue is derived from royalty interests in the Eagle Ford Shale, one of the highest-quality U.S. oil basins. Falcon Minerals acquired the Eagle Ford Shale position in June of 2018 from Blackstone Mineral Partners, L.L.C., a wholly-owned subsidiary of Blackstone Energy.

Falcon Minerals owns mineral, royalty, as well as over-riding royalty interests encompassing roughly 256,000 gross unit acres in the Eagle Ford Shale and Austin Chalk in Karnes, DeWitt, and Gonzales Counties in Texas. In addition, the Company owns roughly 75,000 gross unit acres in the Marcellus Shale across Pennsylvania, Ohio, and West Virginia.

Falcon Minerals has a 22.5 percent royalty interest in ConocoPhillips’ Hooks Ranch position; 75 percent plus is undeveloped. ConocoPhillips permitted 6 new Hooks Ranch wells during September 2020. The wells are expected to be cross unit wells.

Regarding its Hedge Program, Falcon Minerals created a crude oil swap program commencing in July of 2020 through March 2021. The Company created a costless collar hedging program for natural gas commencing in October of 2020 through March 2021. The purpose of the hedge program is to protect its cash flow and balance sheet.

For Q2 2020, Falcon Minerals had Net Production of 4,450 barrels of oil equivalent per day (boe/d) (51 percent oil); production during the quarter was shut-in/curtailed by approximately 25 percent during May and June. Twenty gross, 0.12 net wells were turned in line during Q2 2020.

Moreover, 212 gross line of sight wells (2.52 net wells) were permitted and in active development as of August 3, 2020; 2.52 net line of sight wells includes 1.62 net wells in active development. The Company averaged three rigs running on its Eagle Ford position during Q2 2020.

Falcon Minerals had a Q2 2020 Net Loss of $1.3 million, or $0.01 per Class A share. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was $3.4 million for Q2 2020.

Falcon Minerals Corporation (FLMN), closed Wednesday's trading session at $1.97, even for the day, on 41,436 volume with 407 trades. The average volume for the last 3 months is 150,473 and the stock's 52-week low/high is $1.60000002/$7.25.

POSaBIT Systems Corporation (POSAF)

High Green News, Stockhouse, 1StopTrading, TipRanks, Nasdaq, Invest.com, Simply Wall St, Business Wire, Morningstar, Dividend Investor, Investing News, Wallet Investor, TradingView, GuruFocus, Newsfilecorp, MarketWatch, and Seeking Alpha reported beforehand on POSaBIT Systems Corporation (POSAF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

POSaBIT Systems Corporation is a financial technology company listed on the OTC Markets. It provides unique, advanced, fully-integrated, point of sale (POS) for retailers and dispensaries. The Company provides a total solution for cash-only businesses, such as those within the cannabis industry. POSaBIT Systems has its corporate headquarters in Kirkland, Washington.

The Company provides blockchain-enabled payment processing and POS systems for cash-only businesses, with a special emphasis on the above-mentioned cannabis industry. It specializes in resolving problems for complex, high-risk, developing industries. like cannabis. with an all-in-one solution that is compliant, user-friendly and uses premier hardware.

Software features of POSaBIT Systems’ POS offering include Integrated Online Ordering, Customer Profile & Favorites, Integrated Loyalty, Customer Purchase History, Custom Discounts, Debit Payments, and Product Details. The robust management console allows a user to control their whole business from any location. Hardware features of the POS offering include a Built-in Printer, a Built-in Cash Drawer, and a Swivel Screen.

The Company’s online gateway gives one access to real-time reporting of store performance, customer demographics, as well as transaction data. POSaBIT Systems has incorporated third-party software into its POS system. This means one fewer system to check and update on a daily basis. Moreover, the Company is the only fully-compliant provider of debit payments for cannabis retailers. Debit payments are built into its POS system as part of its blockchain solution. Each month, POSaBIT Systems processes millions of dollars of transactions for merchants across the USA.

POSaBIT Systems previously announced it has brought its full POS solution to the State of Montana. The Company successfully integrated its POS with Montana’s METRC seed-to-sale requirements. POSaBIT has made its solutions available to all Montana medical marijuana dispensaries.

The Montana cannabis market is set to expand its potential with new legislation taking effect this year, which will permit medical marijuana patients to be “untethered” from their previously assigned dispensaries. This will effectively open up the market to more competition and sales among Montana’s 350 medical dispensaries.

POSaBIT Systems Corporation (POSAF), closed Wednesday's trading session at $0.126, up 54.0342%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 10,607 and the stock's 52-week low/high is $0.009999999/$0.25.

Affluence Corporation (AFFU)

Zacks, Stocksbeat, Invest Tribune, Otc.watch, Market Screener, PR Newswire, 4-Traders, Last10k, InvestorsHub, OTC Markets, OilandGas360, Wallet Investor, Morningstar, TradingView, Simply Wall St, and InvestorsHub reported previously on Affluence Corporation (AFFU), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Affluence Corporation is a telecommunications infrastructure company based in Chicago, Illinois. It is a diversified holding company focused on 5G infrastructure businesses. This includes fiber, tower construction and maintenance, base station installation, and other complementary technologies. Affluence’s shares trade on the OTC Markets.

The Company announced recently that it is divesting its interests in its entertainment division to focus on 5G infrastructure and 5G technologies. Affluence has pending LOI's (Letters of Intent) with several 5G infrastructure companies. As part of this strategic emphasis, the Company has named Mr. James E. Honan Jr. as Chief Executive Officer (CEO).

Mr. Honan will lead Affluence and execute the Company's acquisition and integration strategy. Most recently, he was President of Affluence's Telecom vertical. Before that he was a consultant to a number of companies and private equity firms advising on business development and mergers and acquisitions (M&As). Mr. Honan received an MBA in Finance from the Mendoza School of Business at the University of Notre Dame, and a BS in Accounting from Bentley University.

Affluence previously announced that it appointed Mr. Rohan Chanmugam to serve on its Board of Directors. Mr. Chanmugam is Chairman of Clevercoms Ltd., a management consultancy advising the telecommunications, media and technology (TMT) sector. He has greater than three decades of experience in the industry. Further to founding Clevercoms, Mr. Chanmugam was a Senior Vice President at Equant (Orange Business Services), Managing Director BT A&M, Strategic Advisor to the Chief Executive Officer of COLT Telecom, and Non-Executive Director of Host Europe Corporation.

Additionally, Affluence announced that it acquired RAS Engineering, P.A. a telecom infrastructure engineering company based in Miami, Florida. RAS Engineering, P.A. provides the vital design work required for telecommunications construction projects and site plans.

Mr. James Honan, Affluence Chief Executive Officer, said, "The RAS Engineering, P.A. acquisition is the second of several planned acquisitions and brings innovative technology, national engineering licenses and synergistic capabilities to be employed by our acquired companies. RAS Engineering, PA, a nationally-awarded engineering company, has developed a shielding technology that reduces the amount of radiofrequency radiation emitted by 5G base stations…”

Affluence Corporation (AFFU), closed Wednesday's trading session at $0.28, up 87.9195%, on 33,758 volume with 15 trades. The average volume for the last 3 months is 19,784 and the stock's 52-week low/high is $0.108999997/$1.79999995.

Micromem Technologies, Inc. (MMTIF)

MarketWatch, Penny Stock Tweets, Infront Analytics, Equity Clock, InvestorsHub, SmallCapVoice, Dividend Investor, last10k, Xtremepicks, OurHotStockPicks, GuruFocus, Wallet Investor, Stockhouse, Morningstar, Stock Stars, Trading View, PennyStocks24, Capital Cube, Investors Hangout, and Pink Investing reported earlier on Micromem Technologies, Inc. (MMTIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. is a leader in viable Sensor Technology and MRAM (Magnetoresistive Random Access Memory). At present, the Company is focused on magnetic sensor applications via its wholly-owned subsidiary, Micromem Applied Sensor Technologies, Inc. (MAST, Inc.). OTCQB-listed, Micromem Technologies is based in Toronto, Ontario. The MAST, Inc. subsidiary is based in New York, New York.

Micromem’s technologies and solutions include surface functionalization of magnetic nanoparticles; nanoparticle detection platforms to sub-ppb detection levels; customized integration of NEMS/MEMS sensor platforms; magnetic sensor solutions; and sensor-based analytical solution platforms. Technologies and solutions also include structural integrity sensors; wireless suib-surface power solutions; asset protection sensor platforms; and energy storage solutions.

Micromem Technologies designs, develops and provides sensors specific to industry needs. The MAST subsidiary centers on developing and marketing the delivery of inventive magnetic sensor applications in industries including Defense, Life Sciences, Automotive, Consumer, and Mining. MAST develops MEMS/NEMS solutions through combining disparate sensor modalities to create solutions for clients’ problems.

MAST works closely with its clients during development to ensure a smooth transfer to their production facility. MAST is not a product company.

Concerning Energy Storage Solutions, MAST, working together with an energy storage company and a top U.S. utility, is providing sensor technology and overall system and product integration management for the practical realization of a new energy storage system. This system will enable lower costs than building new power generating plants.

Pertaining to its Magnetic Nanoparticle Detection Platform, MAST, working with a leader in the oil industry, has developed an instrument that detects breakthrough water in production oil wells through magnetic and optical sensor techniques.

Recently, Micromem Technologies, via Micromem Applied Sensor Technologies, Inc. (MAST), announced an update on the status of the ATRA 171 project it has been developing over the last 5 years with its oil company partner, Chevron Corporation (NYSE: CVX). With this agreement, the continuing pilot project is proceeding through on site well evaluation. Also, the commercialization plans for this technology are progressing.

Micromem Technologies, Inc. (MMTIF), closed Wednesday's trading session at $0.03723, up 37.8889%, on 158,733 volume with 24 trades. The average volume for the last 3 months is 309,680 and the stock's 52-week low/high is $0.012/$0.128099992.

DroneGuarder, Inc. (DRNG)

OTC Markets, Barchart, StreetRegister.com, Insider Financial, InvestorsHub, 4-Traders, and Emerging Growth.com reported on DroneGuarder, Inc. (DRNG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

DroneGuarder, Inc.  centers on commercializing a drone enhanced home security system as a turnkey solution. The design of its DroneGuarder Mobile App  is to let users have peace of mind within arms length, whether they are in their home or not. Established in San Francisco in 2017,  DroneGuarder has its head office in London, England.

The Company’s solution is app-based. It includes a drone, infrared camera, and an Android mobile app component. Upon an alarm being triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.

The DroneGuarder™ assists in protecting against intruders. Upon an intruder being detected on the sensor net,  one can have the drone fly to the event location. Once there,  one can use the built-in microphone to issue a harsh warning to scare away intruders. If that fails, the high-quality HD film captured of the intruder can be uploaded to the cloud and forwarded to law enforcement agencies.

A variety of DJI drones is available and compatible with the DroneGuarder system. The design of the drones is to respond to commands from a user’s smart phone, and its native remote. This enables one to give it basic orders from anywhere.

DroneGuarder uses Swellpro as its drone supplier. DroneGuarder’s intention is to work jointly to embed its scanning AI image recognition technology into Swellpro’s SD5 drone platform. This will enable the DG Rescue to autonomously grid search for victims in a search area and alert the rescue crews through GPS location and streaming video where the victims are. DroneGuarder will be jointly developing DG Intruder with Swellpro using all the same technology, however it will be app based.

This past January, DroneGuarder announced the launch of its DG App on Google Play. The Company is enhancing the functionality for login and flight control including autonomously and controlled security sweeps. DroneGuarder secured new funding, which enables the Company to fund DG Rescue and DG Intruder product developments through to commercial release.

DroneGuarder believes that once both of its products are launched it will sell 5,000 to 10,000 drone units in the first year. The Company has its channels to market already in place, using Swellpro’s reseller network.

DroneGuarder, Inc. (DRNG), closed Wednesday's trading session at $0.0003, up 50.00%, on 211,000 volume with 4 trades. The average volume for the last 3 months is 20,993,557 and the stock's 52-week low/high is $0.000099999/$0.000799999.

Natcore Technology, Inc. (NTCXF)

Stockhouse, InvestorsHub, MarketWatch, OTC Markets, Business Insider, and StreetInsider reported on Natcore Technology, Inc. (NTCXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Natcore Technology, Inc. concentrates on using its proprietary Foil Cell technology to considerably lower the costs and improve the power output of solar cells. The Company is creating the next generation of solar cells. Natcore is developing two main technologies. These are low-cost, all-back-contact solar cell structures, and Black Silicon cells.

A solar R&D company, Natcore Technology is headquartered in Rochester, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Foil Cell (All Back Contact Solar Cell) uses a high-speed, low temperature laser process. Natcore’s Black Silicon technology streamlines the path to low solar cell reflectance.

Natcore Technology has its Natcore Laboratory in Rochester. This is a 19,000 sq. ft. facility. It has 8,000 sq. ft. of ‘class 10,000’ clean room. The Company engages in the full solar cell process at this laboratory - from bare silicon wafer to working cells.

Regarding the Company’s Foil Cell Structure, the process involves multilayer foil metallization. Key features/properties include low cost contact metals and simplified manufacture. This includes low capital equipment cost, small factory footprint, and low temperature processing.

Natcore Technology has established exclusive licenses and/or joint research agreements with Rice University, the National Renewable Energy Laboratory (NREL), Fraunhofer ISE and the University of Virginia. The Company has received 33 patents; 32 patents are pending.

Recently, Natcore Technology announced it significantly streamlined the fabrication method for its pioneering Natcore Foil Cell™. This allows for even lower-cost production methods.

The Company is targeting greater than 25 percent real-world efficiency for its eventual production solar cells. This is approximately a 25 percent performance improvement over numerous high-end commercial cells being installed today.

The use of laser processing to create the Company’s unique, all-back-contact cell structure has been eliminated and replaced by a carrier selective contact process. This is combined with a foil metallization, which can be inexpensively made with high-speed roll-processing methods. Natcore has started an accelerated development program to produce a prototype with the new process, and also include production cost and efficiency modeling by independent authorities.

Natcore Technology, Inc. (NTCXF), closed Wednesday's trading session at $0.005, up 42.8571%, on 45,721 volume with 3 trades. The average volume for the last 3 months is 29,908 and the stock's 52-week low/high is $0.00075/$0.0247.

The QualityStocks Company Corner

Mobius Interactive Ltd.

The QualityStocks Daily Newsletter would like to spotlight Mobius Interactive Ltd..

In its report focusing on esports, the global consultancy firm PwC states that investors should act now if they want to invest in the esports market. As a company dedicated to bringing together loyalty programs, targeted gamification and product merchandising into one seamless package targeting the 18- to 38-year-old esports community, Mobius Interactive is poised to capitalize on a growing industry that looks to be well on its way to becoming mainstream.

Mobius Interactive Ltd. is an online gaming operator launching in September 2020 with a variety of unique offerings catering to diverse demographic groups. In partnership with Ultra Play, a leading eSports and iGaming platform, Mobius Interactive is seeking to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance customer engagement by leveraging state-of-the-art customer relationship management systems and joint-ventures with over 600 VIP and Master gaming affiliates.

Array of Brands

Mobius Interactive is seeking to target a variety of customer segments and geographies through its diverse brand offerings, including:

  • Aragon Casino: Austria, Finland, the Balkans, Canada, Africa and New Zealand
    Catering to consumers aged 21 to 45, Aragon Casino brands itself along the lines of medieval fantasy, mimicking elements from the likes of The Walking Dead and Game of Thrones.
  • Club Double: Austria, India, Brazil, Finland, Canada, Africa and New Zealand
    Targeting the 30 to 65 age demographic, Club Double is designed to exude a classic yet magical old Hollywood and vintage Miami & Las Vegas air.
  • MobiusBet: Germany, Austria, Switzerland, Brazil, Latin America, New Zealand and India
    MobiusBet is designed to appeal to the 18- to 38-year-old eSports community, bringing together loyalty programs, targeted gamification and product merchandising in one seamless package.

Key Differentiating Indicators

Mobius Interactive has designed its platform with a number of key differentiation traits relative to its target market. These include:

  • The use of affiliates: Mobius Interactive has partnered with over 600 VIP and Master gaming affiliates, who will introduce high-value players to the company’s award-winning iGaming platform. Mobius added over 150 proven affiliates in Europe, Brazil, Finland and New Zealand over a period of just 20 days.
  • eSports Focus: Mobius.Bet, Mobius Interactive’s dedicated eSports hub, will cater to the quickly growing eSports segment, which is expected to rise to a value of $1.7 billion in 2021. With Mobius’ COO being one of the original founders of the eSports.com brand, the company aims to capitalize on this growing segment of the gaming industry.
  • Customer Relationship Management (CRM): Mobius has partnered with Solitics, a new and real-time CRM system, enabling the company to personalize customers’ gaming experiences in an interactive and highly intelligent manner.
  • Loyalty & Gamification: Mobius Interactive is set to introduce a unique loyalty and gamification program designed to increase customer engagement from signup. Loyalty and gamification programs have been proven to increase daily active wagering volumes by 30% while simultaneously increasing daily player activity by 60%. Furthermore, the introduction of these programs can help lower the company’s customer acquisition costs while adding a differentiating element to its platform.

Partnership with Puurl

Puurl provides a solution that embeds eGaming platforms into any existing online e-commerce store. First, shoppers can install the Puurl add-on to their browsers. Then, when visiting their preferred e-commerce stores, players will be prompted to bet, with the potential to win the products they’re browsing. The Puurl solution enables e-commerce operators and eGaming platforms to earn additional gambling revenues – even when their players are shopping. Through its partnership with Puurl, Mobius Interactive will look to add a unique revenue stream to complement its core business operations.

Management Team

Lynn Pearce, CEO, is an experienced, data-driven, commercially focused, strategic brand marketer with over 15 years of proven success in the global gaming industry, from land-based casinos in the UK to online gaming companies offering sports betting, poker and casino games. She was head-hunted to join a startup in Prague that launched 26 casinos, becoming profitable within the first three months of operation, before she relocated to Malta to join a leading B2B casino software development company as head of marketing, where she led global marketing, PR, product development, branding and go-to-market campaigns, retaining full control of a six-month budget of €1 million to increase brand awareness and customer engagement. She recently returned to the B2C side of gaming to launch three new brands in Germany, Brazil and India. She writes articles regularly for Infinity Gaming Magazine and has been a judge for the prestigious International Gaming Awards, a significant event for the gaming industry held each year prior to the largest gaming exhibition of the year, ICE London.

Robin Lawson, Vice President & COO, has been involved in iGaming for over 10 years, successfully founding two VIP casino departments across international locations in Latin America, as well as startup company Tabella in Europe. He most recently co-founded and acted as COO for eSports.com, which raised over $5.5 million as a startup ICO and was sold to German media giant ProSieben. Lawson is also a senior iGaming consultant for startup casino groups and an advisor to blockchain-based tech groups. His long-time experience and proven track record in startup organizations demonstrate his operational leadership skills.

Nicholas de Freitas, Vice President, Marketing, is one of the pioneers of digital stills photography for major retail companies in Africa and Australia. He left to start up UrbanActive, an outsourcing agency, working as marketing project manager and implementing major retail projects. He received his certification in digital marketing from the University of Stellenbosch. He has worked over the past few years as the marketing manager for various poker rooms and casinos, liaising and building relationships with software developers, successfully implementing a number of casino and poker products and holding regular weekly report sessions with the heads of all divisions of the company, spanning South Africa, Canada, Malta, Norway and Costa Rica.

Gary Eldridge, Chairman, is an experienced entrepreneur with a history of working in the venture capital and private equity industry. He is skilled in capital markets, M&A and funding startups and is a strong business development professional. For the past 30 years, he has created and managed numerous public and private companies in Canada, the U.S., Amsterdam, London, Zurich, Dusseldorf, Singapore and Panama. In addition to holding the role of chairman of the company, Eldridge is acting as a mentor to the team, assisting with the financials and structure of the company while allowing the team to be fully focused on Mobius’ growth and operations.

Recent News

chart

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, recently provided its steps for deployment at the U.S. Department of Veterans Affairs. According to the update, the company landed its first U.S. Federal Government contract, deployed its technology and is determining its client’s needs and working hard to meet them. For more details, visit https://ibn.fm/lqqzW.

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (AZRX).

AzurRx BioPharma Inc. (NASDAQ: AZRX) was featured today in a publication from BioMedWire, examining how the use of artificial intelligence (AI) in the development of coronavirus vaccines, which started barely three months after the virus was first identified in China, has revolutionized the way vaccines are developed. According to the World Health Organization, in September 34 different vaccines were being tested in humans and an additional 145 vaccine candidates had tests being conducted in the lab or on animals. These are surprising numbers, especially considering that it takes years, sometimes decades, to develop a vaccine. Up until the COVID-19 outbreak, the mumps vaccine was the fastest-produced vaccine with a four-year record of development, from sample collection to its marketed form.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Wednesday's trading session at $0.7085, up 1.2143%, on 16,633 volume with 70 trades. The average volume for the last 3 months is 344,443 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)  was featured today in a publication from MiningNewsWire, examining how, in order to keep operations on your mining site running without hitches, you need up-to-date training for your workers. Onsite training allows mine technicians to stay updated in a digital age that is constantly evolving and equips them with knowledge that allows them to understand how various equipment works. This training is in addition to essential training on how equipment should be used and how to use it optimally.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Wednesday's trading session at $0.3094, up 4.07%, on 54,600 volume with 9 trades. The stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process quality assurance software for the commercial 3D metal printing industry, was featured in a research report following release of its third quarter earnings results. In the report, the publisher — Trickle Research, maintains an allocation: 5 rating and price target of $17 per share. “We think the conference call and the summation of the announcements/achievements from the past six months substantially support our bullish view of Sigma,” David L. Lavigne, senior analyst and managing partner at Trickle Research, states in the report. “Sigma Labs is clearly gathering fundamental sales (and operating) momentum.” To view the full report, visit http://ibn.fm/ZlZiT

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $2.18, up 2.8302%, on 92,853 volume with 368 trades. The average volume for the last 3 months is 1,433,484 and the stock's 52-week low/high is $1.95000004/$11.6999998.

Recent News

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)

The QualityStocks Daily Newsletter would like to spotlight Processa Pharmaceuticals Inc. (NASDAQ: PCSA).

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) was featured today in a publication from BioMedWire, examining how, in a study published in the “IEEE Sensors Journal” on Sept. 25, 2020, scientists developed a sensor that can be integrated in dental implants to monitor bone growth. This avoids the need for multiple X-rays of the jaw. Presently, dentists use X-rays to observe jaw health after a patient gets a dental implant. Dental X-rays require low doses of radiation, and we all know that undergoing too many X-rays isn’t good for human health. This new sensor, on the other hand, not only passively monitors bone growth but also reduces the frequency with which patients neet X-rays after receiving dental implants. This reduced need for X-rays is a main motivation for designing the sensor. Also today, the company was featured in a BioMedNewsBreaks from BioMedWire, examining how PCSA was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership rights to five programs that are de-risked by existing data. To view the full report, visit http://ibn.fm/i1aFT

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (FDA) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

  1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
  2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
  3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis (IPF) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), closed Wednesday's trading session at $4.19, even for the day, on 19,487 volume with 104 trades. The average volume for the last 3 months is 27,726 and the stock's 52-week low/high is $3.40000009/$18.00.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

In a letter to shareholders thanking them for their support, Sugarmade (OTCQB: SGMD) CEO Jimmy Chan outlined the “building blocks of a coherent and cohesive strategic vision” and noted that the company is putting in motion “key next steps to manifest that vision and drive strong and sustained shareholder value as a key emerging leader in the California cannabis marketplace”(https://cnw.fm/C3Q5i).

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Wednesday's trading session at $0.0014, even for the day, on 14,501,013 volume with 83 trades. The average volume for the last 3 months is 39,037,687 and the stock's 52-week low/high is $0.001249999/$0.019799999.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) was featured today in the 420 with CNW by CannabisNewsWire. Although the nascent cannabis industry is among the fastest-growing sectors in the world, it is plagued by challenges. For instance, because cultivating, researching and selling cannabis was prohibited for decades, cultivars have limited genetic knowledge and breeding resources. This puts the industry at a severe disadvantage against other crops that have undergone genetic research and experimentation to create superior genetics.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Wednesday's trading session at $0.20, even for the day, on 5,500 volume with 3 trades. The average volume for the last 3 months is 12,745 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company’s (NASDAQ: WTER) (CSE: WTER) flagship brand, Alkaline88(r), was the No. 1 item by cases sold at the recent KeHE Virtual Winter Show. The company produces premium bottled alkaline water, flavor-infused waters and CBD-infused products sold under the brand names Alkaline88, A88 Infused(TM) and A88CBD(TM), respectively. Held Oct. 5–12, 2020, the winter show is sponsored by KeHE, which has a nationwide distribution network comprised of an estimated 12,000 customers representing more than 30,000 accounts. To view the full press release, visit http://cnw.fm/0XqEs. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. If you have no experience with edibles, you can be easily overwhelmed if you have to purchase some. In the United States, all types of dosages and types of edibles are available, and a bad purchase may lead to bad highs. Despite this, some marijuana users enjoy edibles so much that they choose edibles over all other cannabis consumption methods. Some people assert that edibles are healthier than smoking and vaping with regard to the lungs, plus they produce stronger results. Edibles may also induce a stronger response in the mind or body as well as potentially provide more pain relief.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Wednesday's trading session at $1.28, off by 2.2901%, on 386,425 volume with 1,159 trades. The average volume for the last 3 months is 1,288,046 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how, if you’ve been thinking about buying a plug-in car to reduce your reliance on fossil fuels, you aren’t alone. The past few years have seen an increasing number of consumers with interest in battery electric vehicles (“EVs”) and plug-in vehicles that don’t rely solely on gasoline. However, while conventional vehicles mostly focus on hardware, plug-ins employ software as well, making the shopping experience quite different.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday's trading session at $6.17, off by 3.8941%, on 244,698 volume with 1,615 trades. The average volume for the last 3 months is 1,314,012 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced that it will release financial results for its second quarter ended September 30, 2020, on Thursday, Nov. 12, 2020, as well as host a conference call at 9:00 a.m. Eastern Time. According to the update, Erez Raphael, chief executive officer, Rick Anderson, president and general manager of North America and Zvi Ben-David, chief financial officer will host the call. Interested parties may register via the webcast link and join the call by dialing 844-369-8770 (Toll-Free) or 862-298-0840 (International) and providing the following conference ID: DarioHealth Third Quarter 2020 Earnings Call and Webcast. To view the full press release, visit http://ibn.fm/D1k6t

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Wednesday's trading session at $11.78, off by 1.34%, on 60,128 volume with 635 trades. The average volume for the last 3 months is 163,575 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR) on Tuesday announced that, due to technical issues, its conference call and webcast originally scheduled for Nov. 3, 2020, has been postponed to be held at 4:00 pm ET on Nov. 4, 2020. Interested parties may join the webcast and access presentations and viewer-controlled slides via the following link: https://ibn.fm/7EfVh. In addition, participants may dial 1-888-664-6392 (toll free in the U.S. and Canada) to join the webcast and ask questions. A recorded version will be available shortly after conclusion of the webcast by dialing 1-888-390-0541 (toll free in the U.S. and Canada) and entering code 303725#. To view the full press release, visit http://ibn.fm/v0RBP

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $1.49, off by 1.3245%, on 785,734 volume with 2,537 trades. The average volume for the last 3 months is 1,312,452 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Wednesday's trading session at $1.15, off by 28.125%, on 2,096 volume with 12 trades. The average volume for the last 3 months is 3,255 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness (NASDAQ: JUPW), a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (“CBD”) via a multitude of convenient products, announced the closing of its initial public offering. The IPS comprised 933,333 units consisting of one share of common stock and one warrant, with gross proceeds of $7 million before offering expenses are deducted. The units were traded under the symbols of “JUPW” and “JUPWW” on the Nasdaq Capital Market beginning Oct. 30, 2020. Aegis Capital Corporation, which acted as the sole book running manager for the offering, also exercised an option to purchase up to 140,000 warrants. On Oct. 30, 2020, the Securities and Exchange Commission declared effective a registration statement regarding the securities sold in this IPO, which was being made by means of a prospectus only. To view the full press release, visit http://cnw.fm/1ucv6

Jupiter Wellness (NASDAQ: JUPW) is a functional wellness and natural health products company. Through its proprietary line of offerings leveraging the therapeutic and medical benefits of cannabidiol (CBD), the company is dedicated to advancing research into CBD for treatment and relief of a range of ailments, including ultraviolet exposure, psoriasis, eczema, skin aging and other conditions.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

An Award-Winning Brand Portfolio

Jupiter Wellness currently markets seven unique CBD brands targeted toward specific niches of the larger CBD space. These brands include:

  • CaniSun – This line of products is dermatologist tested and recommended. Its high-performance, ultra-moisturizing formulas provide protection from UVA, UVB and IRA rays while defending skin against photo-aging and dehydration.
  • fitCBD – This line is ideal for athletes of all levels seeking to incorporate CBD into their training regimens. fitCBD proudly incorporates natural, proven essential oils and cutting-edge CBD technology in a selection of vegan, natural and cruelty-free formulations.
  • Wellness CBD – This brand includes products designed to provide immediate support through a proprietary combination of essential oils and industrial hemp-derived CBD.
  • Black Belt CBD – This brand features products formulated to offer immediate relief for the most exhausted and stressed muscles. Menthol provides immediate cooling action, while a proprietary essential oil blend helps boost recovery time.
  • Bella – This product line includes a wide selection of luxury skin and hair products designed to boost lift and shine by leveraging the antioxidant power of CBD.
  • Felix & Ambrosia – This brand features premium CBD-infused foot cream formulated to provide immediate relief for long days in high heels and boots, as well as award-winning flavored lube available in five tantalizing flavors.
  • Jack – This line of CBD-infused creams, serums and moisturizers is designed to meet all of the skincare needs of even the most rugged of adventurers.

Jupiter Wellness retails its full portfolio of brands and products on its ecommerce site, www.CBDCaring.com.

Share Offering

On October 13, 2020, Jupiter Wellness filed a preliminary prospectus with the U.S. Securities and Exchange Commission detailing plans to offer one million units consisting of one share of common stock and one warrant in a firm commitment initial public offering at an assumed price of $7.50 per unit (https://ibn.fm/jGmkc). Each warrant is immediately exercisable and entitles the holder to purchase one share of common stock at an exercise price of $8.50. Warrants will expire five years from the date of issuance.

In line with this proposed offering, the company has been approved to list its shares and warrants for trading on the Nasdaq Capital Market, subject to official notice of issuance, under ticker symbols ‘JUPW’ and ‘JUPWW’, respectively.

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a highly successful financial consulting firm specializing in assisting emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Richard Miller is the COO of Jupiter Wellness. Since 2000, Miller has managed a consulting firm that advises emerging growth companies. Over the last 20 years, he has provided strategic advice to hundreds of companies across diverse industries. He has assisted C-Level executives with expanding, financing and other challenges facing emerging companies. Miller co-founded Teeka Tan Suncare Products. Prior to the company’s sale, he was instrumental in the design and launch of a full line of boutique suncare products. He managed the deal from concept to sale. He is an advocate for school safety and local schools through his grass roots group, ‘My School Counts’.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory and operation experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Wednesday's trading session at $4.07, off by 16.9388%, on 116,272 volume with 676 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $4.00/$7.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.